ACELYRIN INC.
0.810
USD
(-37.93%)
04/24/2025 - 13:30
Halted 15 min delayed data - NASDAQ Stocks
| Open: | 1.380 |
| Change: | -0.495 |
| Volume: | 71 |
| Low: | 0.810 |
| High: | 1.630 |
| High / Low range: | 0.820 |
| Type: | Stocks |
| Ticker: | SLRN |
| ISIN: |
ACELYRIN INC. news, videos and press releases
For more news please use our advanced search feature.
ACELYRIN INC. - More news...
ACELYRIN INC. - More news...
- 04/21/2025 - 10:30 Alumis and ACELYRIN Announce Amended Merger Agreement
- 03/13/2025 - 11:00 ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
- 03/04/2025 - 14:01 ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
- 03/04/2025 - 14:00 ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
- 02/21/2025 - 02:00 ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
- 02/06/2025 - 21:15 Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
- 01/06/2025 - 21:00 ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease
- 01/03/2025 - 01:00 ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
- 12/10/2024 - 21:30 ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
- 11/13/2024 - 21:00 ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
- 11/06/2024 - 21:00 ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
- 10/16/2024 - 11:00 ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
- 09/19/2024 - 11:00 ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
- 09/10/2024 - 11:00 ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery
- 08/22/2024 - 11:00 ACELYRIN, INC. to Participate in Upcoming Investor Conferences
- 08/13/2024 - 20:00 ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
- 08/06/2024 - 20:30 ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
- 06/05/2024 - 11:00 ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
- 05/29/2024 - 11:00 ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
- 05/09/2024 - 12:01 ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
- 05/09/2024 - 12:00 ACELYRIN, INC. Announces Leadership Transition
- 04/29/2024 - 20:05 ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
- 03/28/2024 - 20:05 ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
- 03/20/2024 - 11:00 ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
- 03/11/2024 - 12:02 ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
- 03/11/2024 - 12:00 ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
- 02/15/2024 - 21:05 ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
- 01/10/2024 - 07:00 SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses of $100,000 to Contact the Firm
- 01/05/2024 - 06:00 SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses of $100,000 to Contact the Firm
- 12/20/2023 - 21:30 ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors
